Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

High-dose chemotherapy combined with autologous peripheral blood stem cell transplantation in children with advanced malignant solid tumors: A retrospective analysis of 38 cases.

Zhang WL, Zhang YI, Zhi T, Huang DS, Wang YZ, Hong L, Zhu X, Liu AP, Hu HM.

Oncol Lett. 2015 Aug;10(2):1047-1053. Epub 2015 May 27.

2.

Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma.

Tsang PS, Cheuk AT, Chen QR, Song YK, Badgett TC, Wei JS, Khan J.

BMC Cancer. 2012 Mar 21;12:101. doi: 10.1186/1471-2407-12-101.

3.

Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.

Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, Shaw PJ, Cohn SL, Matthay KK.

J Clin Oncol. 2011 Nov 20;29(33):4351-7. doi: 10.1200/JCO.2010.34.3293. Epub 2011 Oct 17.

4.

Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions.

Wagner L.

Sarcoma. 2011;2011:957957. doi: 10.1155/2011/957957. Epub 2011 Apr 6.

5.

Current therapeutic approaches in metastatic and recurrent ewing sarcoma.

Huang M, Lucas K.

Sarcoma. 2011;2011:863210. doi: 10.1155/2011/863210. Epub 2010 Dec 1.

6.

The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.

Levy AG, Zage PE, Akers LJ, Ghisoli ML, Chen Z, Fang W, Kannan S, Graham T, Zeng L, Franklin AR, Huang P, Zweidler-McKay PA.

Invest New Drugs. 2012 Feb;30(1):191-9. doi: 10.1007/s10637-010-9551-y. Epub 2010 Oct 5.

Supplemental Content

Support Center